Principle 6. Respect the rights of security holders The Board strives to communicate effectively with shareholders, give them ready access to balanced and understandable information about the business and make it easy for them to participate in shareholder meetings. In accordance with Recommendation 6.1, comprehensive information about the Company and its governance is provided via the website www.neurenpharma.com. This includes information about the Board and senior executives, as well as corporate governance policies. All announcements, presentations, financial information and meetings materials disclosed to the ASX are placed on the website, so that current and historical information can be accessed readily. The Company’s investor relations program facilitates effective two-way communication with investors (Recommendation 6.2). The Chief Executive Officer interacts with institutional investors, private investors, analysts and media at regular bank investor conferences, roadshows, retail investor events and scheduled interviews, as well as ad-hoc meetings, conducting meetings in person or by video/teleconference and responding personally to enquiries. The Board seeks practical and cost-effective ways to promote informed participation at shareholder meetings (Recommendation 6.3). This includes providing access to clear and comprehensive meeting materials and electronic proxy voting. The Annual Shareholders’ Meeting in 2025 was conducted as a hybrid meeting, with participation both inperson and by electronic means. All resolutions at the Company’s Annual Shareholders’ Meeting in 2025 were decided by a poll (Recommendation 6.4) In accordance with Recommendation 6.5, shareholders are provided with and encouraged to use electronic methods to communicate with the Company and with the share registry. Principle 7. Recognise and manage risk The Board has established policies for the oversight and management of material business risks, a summary of which is available on the Neuren website. The Board does not have a separate committee to oversee risk, judging that the whole Board is better able to conduct that function efficiently and effectively, given the small size of the Board and the specialised nature of the business (Recommendation 7.1). In accordance with Recommendation 7.2, the Board reviews the Group’s risk management framework at least annually to satisfy itself that it continues to be sound. A review was conducted in 2025. The size and complexity of the Group’s business is not sufficient to warrant an internal audit function (Recommendation 7.3). The risk management policy is designed to involve the entire organisation in risk management and to ensure that the effectiveness of the risk management and internal control processes are continually improved. The Board has considered whether the Group has any material exposure to environmental or social sustainability risks, including climate‑related risks, having regard to the nature and scale of its current operations. As the Group is primarily research‑focused and does not operate or control research laboratories, manufacturing facilities or other emissions‑intensive activities, the Board considers that the Group’s exposure to such risks is not material at this stage. The Board will continue to monitor sustainability‑related risks as the Group’s activities evolve (Recommendation 7.4). Each year, Neuren’s Board reviews and approves Neuren’s Modern Slavery Statement as required by the Australian Modern Slavery Act 2018. The Statement details the steps the Group undertakes to identify, assess and address modern slavery risks. Neuren’s most recent Statement was approved by the Board in June 2025. Principle 8. Remunerate fairly and responsibly Neuren believes having highly skilled and motivated people will allow the organisation to best pursue its mission and achieve its goals for the benefit of shareholders and stakeholders more broadly. The ability to attract and retain the best people is critical to the Company’s future success. The Board believes remuneration policies are a key part of ensuring this success. The Board has a Remuneration Committee, which consists of only independent non-executive directors, has at least three members and is chaired by an independent director as suggested in Recommendation 8.1. The Committee met three times during 2025. The Committee operates under a charter approved by the Board, a summary of which is available on the Neuren website. It is responsible for undertaking a broad review of, supporting compliance with, and making recommendations in respect of, the Group’s remuneration policies. It is also responsible for: – setting and reviewing compensation policies and practices of the Company; – setting and reviewing all elements of remuneration of the directors and members of the executive team; and – setting and reviewing long term incentive plans for employees and/or directors. In undertaking these tasks the Remuneration Committee meets separately with management where required. ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) CONTINUED Neuren Pharmaceuticals Limited Annual Report 2025 29
RkJQdWJsaXNoZXIy MjE2NDg3